AAV Gene Therapy Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on AAV Gene Therapy Market 

5.1. COVID-19 Landscape: AAV Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global AAV Gene Therapy Market, By Therapeutic Area/Disease Indication

8.1. AAV Gene Therapy Market, by Therapeutic Area/Disease Indication

8.1.1. Neurological Disorders

8.1.1.1. Market Revenue and Forecast  

8.1.2. Ophthalmic Disorders

8.1.2.1. Market Revenue and Forecast  

8.1.3. Hematologic Disorders

8.1.3.1. Market Revenue and Forecast  

8.1.4. Muscular Disorders

8.1.4.1. Market Revenue and Forecast  

8.1.5. Metabolic Disorders

8.1.5.1. Market Revenue and Forecast  

8.1.6. Rare Genetic Disorders (Other)

8.1.6.1. Market Revenue and Forecast  

8.1.7. Oncology/Cancer

8.1.7.1. Market Revenue and Forecast  

Chapter 9. Global AAV Gene Therapy Market, By Vector Serotype

9.1. AAV Gene Therapy Market, by Vector Serotype

9.1.1. AAV1

9.1.1.1. Market Revenue and Forecast  

9.1.2. AAV2

9.1.2.1. Market Revenue and Forecast  

9.1.3. AAV3

9.1.3.1. Market Revenue and Forecast  

9.1.4. AAV4

9.1.4.1. Market Revenue and Forecast  

9.1.5. AAV5

9.1.5.1. Market Revenue and Forecast  

9.1.6. AAV6

9.1.6.1. Market Revenue and Forecast  

9.1.7. AAV7

9.1.7.1. Market Revenue and Forecast  

9.1.8. AAV8

9.1.8.1. Market Revenue and Forecast  

9.1.9. AAV9

9.1.9.1. Market Revenue and Forecast  

9.1.10. AAV10

9.1.10.1. Market Revenue and Forecast  

9.1.11. AAV11

9.1.11.1. Market Revenue and Forecast  

9.1.12. AAV12

9.1.12.1. Market Revenue and Forecast  

9.1.13. Engineered/Synthetic/Hybrid Capsids

9.1.13.1. Market Revenue and Forecast  

Chapter 10. Global AAV Gene Therapy Market, By Route of Administration

10.1. AAV Gene Therapy Market, by Route of Administration

10.1.1. Intravenous (I.V.)

10.1.1.1. Market Revenue and Forecast  

10.1.2. Intrathecal (I.T.) (for CNS delivery)

10.1.2.1. Market Revenue and Forecast  

10.1.3. Intraocular (I.O.) (e.g., intravitreal, subretinal)

10.1.3.1. Market Revenue and Forecast  

10.1.4. Intramuscular (I.M.)

10.1.4.1. Market Revenue and Forecast  

10.1.5. Intracerebral

10.1.5.1. Market Revenue and Forecast  

10.1.6. Subcutaneous

10.1.6.1. Market Revenue and Forecast  

10.1.7. Local/Direct Injection (e.g., into specific organs)

10.1.7.1. Market Revenue and Forecast  

Chapter 11. Global AAV Gene Therapy Market, By Application Stage

11.1. AAV Gene Therapy Market, by Application Stage

11.1.1. Preclinical Therapies

11.1.1.1. Market Revenue and Forecast  

11.1.2. Clinical Therapies

11.1.2.1. Market Revenue and Forecast  

11.1.3. Commercialized Therapies

11.1.3.1. Market Revenue and Forecast  

Chapter 12. Global AAV Gene Therapy Market, By Manufacturing Type

12.1. AAV Gene Therapy Market, by Manufacturing Type

12.1.1. In-house Manufacturing

12.1.1.1. Market Revenue and Forecast  

12.1.2. CDMOs/Vector Production Facilities

12.1.2.1. Market Revenue and Forecast  

Chapter 13. Global AAV Gene Therapy Market, By End-User

13.1. AAV Gene Therapy Market, by End-User

13.1.1. Pharmaceutical and Biotechnology Companies

13.1.1.1. Market Revenue and Forecast  

13.1.2. Academic and Research Institutes

13.1.2.1. Market Revenue and Forecast  

13.1.3. Contract Research Organizations (CROs)

13.1.3.1. Market Revenue and Forecast  

Chapter 14. Global AAV Gene Therapy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.1.2. Market Revenue and Forecast, by Vector Serotype  

14.1.3. Market Revenue and Forecast, by Route of Administration  

14.1.4. Market Revenue and Forecast, by Application Stage  

14.1.5. Market Revenue and Forecast, by Manufacturing Type  

14.1.6. Market Revenue and Forecast, by End-User  

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.1.7.2. Market Revenue and Forecast, by Vector Serotype  

14.1.7.3. Market Revenue and Forecast, by Route of Administration  

14.1.7.4. Market Revenue and Forecast, by Application Stage  

14.1.8. Market Revenue and Forecast, by Manufacturing Type  

14.1.8.1. Market Revenue and Forecast, by End-User   

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.1.9.2. Market Revenue and Forecast, by Vector Serotype  

14.1.9.3. Market Revenue and Forecast, by Route of Administration  

14.1.9.4. Market Revenue and Forecast, by Application Stage  

14.1.10. Market Revenue and Forecast, by Manufacturing Type  

14.1.11. Market Revenue and Forecast, by End-User  

14.2. Europe

14.2.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.2.2. Market Revenue and Forecast, by Vector Serotype  

14.2.3. Market Revenue and Forecast, by Route of Administration  

14.2.4. Market Revenue and Forecast, by Application Stage   

14.2.5. Market Revenue and Forecast, by Manufacturing Type  

14.2.6. Market Revenue and Forecast, by End-User  

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.2.8.2. Market Revenue and Forecast, by Vector Serotype  

14.2.8.3. Market Revenue and Forecast, by Route of Administration  

14.2.9. Market Revenue and Forecast, by Application Stage   

14.2.10. Market Revenue and Forecast, by Manufacturing Type  

14.2.10.1. Market Revenue and Forecast, by End-User   

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.2.11.2. Market Revenue and Forecast, by Vector Serotype  

14.2.11.3. Market Revenue and Forecast, by Route of Administration  

14.2.12. Market Revenue and Forecast, by Application Stage  

14.2.13. Market Revenue and Forecast, by Manufacturing Type  

14.2.14. Market Revenue and Forecast, by End-User  

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.2.15.2. Market Revenue and Forecast, by Vector Serotype  

14.2.15.3. Market Revenue and Forecast, by Route of Administration  

14.2.15.4. Market Revenue and Forecast, by Application Stage  

14.2.16. Market Revenue and Forecast, by Manufacturing Type  

14.2.16.1. Market Revenue and Forecast, by End-User  

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.2.17.2. Market Revenue and Forecast, by Vector Serotype  

14.2.17.3. Market Revenue and Forecast, by Route of Administration  

14.2.17.4. Market Revenue and Forecast, by Application Stage  

14.2.18. Market Revenue and Forecast, by Manufacturing Type  

14.2.18.1. Market Revenue and Forecast, by End-User  

14.3. APAC

14.3.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.3.2. Market Revenue and Forecast, by Vector Serotype  

14.3.3. Market Revenue and Forecast, by Route of Administration  

14.3.4. Market Revenue and Forecast, by Application Stage  

14.3.5. Market Revenue and Forecast, by Manufacturing Type  

14.3.6. Market Revenue and Forecast, by End-User  

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.3.7.2. Market Revenue and Forecast, by Vector Serotype  

14.3.7.3. Market Revenue and Forecast, by Route of Administration  

14.3.7.4. Market Revenue and Forecast, by Application Stage  

14.3.8. Market Revenue and Forecast, by Manufacturing Type  

14.3.9. Market Revenue and Forecast, by End-User  

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.3.10.2. Market Revenue and Forecast, by Vector Serotype  

14.3.10.3. Market Revenue and Forecast, by Route of Administration  

14.3.10.4. Market Revenue and Forecast, by Application Stage  

14.3.11. Market Revenue and Forecast, by Manufacturing Type  

14.3.11.1. Market Revenue and Forecast, by End-User  

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.3.12.2. Market Revenue and Forecast, by Vector Serotype  

14.3.12.3. Market Revenue and Forecast, by Route of Administration  

14.3.12.4. Market Revenue and Forecast, by Application Stage  

14.3.12.5. Market Revenue and Forecast, by Manufacturing Type  

14.3.12.6. Market Revenue and Forecast, by End-User  

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.3.13.2. Market Revenue and Forecast, by Vector Serotype  

14.3.13.3. Market Revenue and Forecast, by Route of Administration  

14.3.13.4. Market Revenue and Forecast, by Application Stage  

14.3.13.5. Market Revenue and Forecast, by Manufacturing Type  

14.3.13.6. Market Revenue and Forecast, by End-User  

14.4. MEA

14.4.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.4.2. Market Revenue and Forecast, by Vector Serotype  

14.4.3. Market Revenue and Forecast, by Route of Administration  

14.4.4. Market Revenue and Forecast, by Application Stage  

14.4.5. Market Revenue and Forecast, by Manufacturing Type  

14.4.6. Market Revenue and Forecast, by End-User  

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.4.7.2. Market Revenue and Forecast, by Vector Serotype  

14.4.7.3. Market Revenue and Forecast, by Route of Administration  

14.4.7.4. Market Revenue and Forecast, by Application Stage  

14.4.8. Market Revenue and Forecast, by Manufacturing Type  

14.4.9. Market Revenue and Forecast, by End-User  

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.4.10.2. Market Revenue and Forecast, by Vector Serotype  

14.4.10.3. Market Revenue and Forecast, by Route of Administration  

14.4.10.4. Market Revenue and Forecast, by Application Stage  

14.4.11. Market Revenue and Forecast, by Manufacturing Type  

14.4.12. Market Revenue and Forecast, by End-User  

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.4.13.2. Market Revenue and Forecast, by Vector Serotype  

14.4.13.3. Market Revenue and Forecast, by Route of Administration  

14.4.13.4. Market Revenue and Forecast, by Application Stage  

14.4.13.5. Market Revenue and Forecast, by Manufacturing Type  

14.4.13.6. Market Revenue and Forecast, by End-User  

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.4.14.2. Market Revenue and Forecast, by Vector Serotype  

14.4.14.3. Market Revenue and Forecast, by Route of Administration  

14.4.14.4. Market Revenue and Forecast, by Application Stage  

14.4.14.5. Market Revenue and Forecast, by Manufacturing Type  

14.4.14.6. Market Revenue and Forecast, by End-User  

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.5.2. Market Revenue and Forecast, by Vector Serotype  

14.5.3. Market Revenue and Forecast, by Route of Administration  

14.5.4. Market Revenue and Forecast, by Application Stage  

14.5.5. Market Revenue and Forecast, by Manufacturing Type  

14.5.6. Market Revenue and Forecast, by End-User  

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.5.7.2. Market Revenue and Forecast, by Vector Serotype  

14.5.7.3. Market Revenue and Forecast, by Route of Administration  

14.5.7.4. Market Revenue and Forecast, by Application Stage  

14.5.8. Market Revenue and Forecast, by Manufacturing Type  

14.5.8.1. Market Revenue and Forecast, by End-User  

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Therapeutic Area/Disease Indication  

14.5.9.2. Market Revenue and Forecast, by Vector Serotype  

14.5.9.3. Market Revenue and Forecast, by Route of Administration  

14.5.9.4. Market Revenue and Forecast, by Application Stage  

14.5.9.5. Market Revenue and Forecast, by Manufacturing Type  

14.5.9.6. Market Revenue and Forecast, by End-User  

Chapter 15. Company Profiles

15.1. Advanced Energy Industries, Inc.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. MKS Instruments, Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Samco Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. PVA TePla AG

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Axcelis Technologies, Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Lam Research Corporation

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. ULVAC, Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Plasma Etch, Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. PIE Scientific LLC

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Tokyo Electron Limited (TEL)

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms